Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

Astellas Pharma Inc

Overview

The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Type 2 Diabetes Mellitus Diabetes Mellitus, Type II

Interventions

nateglinideDRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes mellitus under the treatment with pioglitazone Exclusion Criteria: * Patients who cannot follow the diet therapy and/or exercise therapy * Type 1 diabetes mellitus

Locations (7)

Unnamed facility

Chubu Region, Japan

Unnamed facility

Chugoku Region, Japan

Unnamed facility

Hokkaido Region, Japan

Unnamed facility

Kanto Region, Japan

Unnamed facility

Kinki Region, Japan

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.